Baird Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $280
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Resmed (RMD)
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Announces Target Price $270
Resmed Poised for Growth Amid Rising OSA Diagnosis and Market Opportunity: Buy Rating Reaffirmed With Increased Price Objective
ResMed (NYSE:RMD) Eyes Growth With Board Expansion and Solid Earnings Despite Freight Cost Challenges
Baird Starts ResMed at Outperform, Cites Growing Sleep Apnea Market